MDT

83.58

-0.61%↓

VEEV

225.8

+0.45%↑

A

105.71

+0.08%↑

WBA

10.98

-0.18%↓

CHE

548.09

-0.97%↓

MDT

83.58

-0.61%↓

VEEV

225.8

+0.45%↑

A

105.71

+0.08%↑

WBA

10.98

-0.18%↓

CHE

548.09

-0.97%↓

MDT

83.58

-0.61%↓

VEEV

225.8

+0.45%↑

A

105.71

+0.08%↑

WBA

10.98

-0.18%↓

CHE

548.09

-0.97%↓

MDT

83.58

-0.61%↓

VEEV

225.8

+0.45%↑

A

105.71

+0.08%↑

WBA

10.98

-0.18%↓

CHE

548.09

-0.97%↓

MDT

83.58

-0.61%↓

VEEV

225.8

+0.45%↑

A

105.71

+0.08%↑

WBA

10.98

-0.18%↓

CHE

548.09

-0.97%↓

Search

Boston Scientific Corp.

Open

SectorGezondheidszorg

101.16 0.66

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

100.42

Max

101.95

Belangrijke statistieken

By Trading Economics

Inkomsten

-138M

562M

Verkoop

352M

4.6B

K/W

Sectorgemiddelde

74.864

57.333

EPS

0.7

Winstmarge

12.322

Werknemers

53,000

EBITDA

-41M

1B

Aanbevelingen

By TipRanks

Aanbevelingen

Strong Buy

12 Maanden Prognose

+18.99% upside

Dividenden

By Dow Jones

Volgende Winsten

23 jul 2025

Marktinformatie

By TradingEconomics

Marktkapitalisatie

-14B

138B

Vorige openingsprijs

100.5

Vorige sluitingsprijs

101.16

Technische score

By Trading Central

Vertrouwen

Strong Bullish Evidence

Boston Scientific Corp. Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

23 apr 2025, 12:16 UTC

Winsten
Belangrijke Marktbewegers

Boston Scientific Shares Higher on Rosy Outlook, 1Q Beats

3 mrt 2025, 12:35 UTC

Acquisities, Fusies, Overnames

Boston Scientific to Buy Rest of SoniVie for Initial $360 Million

5 feb 2025, 12:23 UTC

Winsten

Boston Scientific 4Q Profit Up on Strong Cardio Device Sales

23 apr 2025, 10:32 UTC

Winsten

Boston Scientific Sees 2Q Reported Sales Up 17.5%-19.5%, Organic Sales Up 13%-15% >BSX

23 apr 2025, 10:31 UTC

Winsten

Boston Scientific Sees 2025 Reported Sales Up 15%-17%, Organic Sales Up 12%-14% >BSX

23 apr 2025, 10:30 UTC

Winsten

Boston Scientific 1Q EPS 45c >BSX

23 apr 2025, 10:30 UTC

Winsten

Boston Scientific 1Q Adj EPS 75c >BSX

23 apr 2025, 10:30 UTC

Winsten

Boston Scientific Sees FY Adj EPS $2.87-Adj EPS $2.94 >BSX

23 apr 2025, 10:30 UTC

Winsten

Boston Scientific 1Q Sales $4.66B >BSX

23 apr 2025, 10:30 UTC

Winsten

Boston Scientific Sees 2Q Adj EPS 71c-Adj EPS 73c >BSX

23 apr 2025, 10:30 UTC

Winsten

Boston Scientific Sees 2Q EPS 45c-EPS 47c >BSX

23 apr 2025, 10:30 UTC

Winsten

Boston Scientific 1Q Organic Sales Up 18.2% >BSX

23 apr 2025, 10:30 UTC

Winsten

Boston Scientific Sees FY EPS $1.86-EPS $1.93 >BSX

3 mrt 2025, 11:59 UTC

Acquisities, Fusies, Overnames

Boston Scientific to Pay Up to Additional $180 Million Upon Achievement of Regulatory Milestone >BSX

3 mrt 2025, 11:58 UTC

Acquisities, Fusies, Overnames

Boston Scientific to Buy Rest of SoniVie for Initial $360 Million >BSX

3 mrt 2025, 11:58 UTC

Acquisities, Fusies, Overnames

Boston Scientific Announces Agreement To Acquire SoniVie Ltd. >BSX

5 feb 2025, 21:33 UTC

Winsten

How Boston Sci Leaned On Its New Heart Device For A Fourth-Quarter Beat -- IBD

5 feb 2025, 15:20 UTC

Winsten

How Boston Sci Leaned On Its New Heart Device For A Fourth-Quarter Beat -- IBD

5 feb 2025, 11:39 UTC

Winsten

Boston Scientific Sees 1Q Organic Sales Up 14%-16% >BSX

5 feb 2025, 11:39 UTC

Winsten

Boston Scientific Sees 1Q Sales Up 17%-19% >BSX

5 feb 2025, 11:38 UTC

Winsten

Boston Scientific Sees 2025 Organic Sales Up 10%-12% >BSX

5 feb 2025, 11:38 UTC

Winsten

Boston Scientific Sees 2025 Sales Up 12.5%-14.5% >BSX

5 feb 2025, 11:37 UTC

Winsten

Boston Scientific 4Q Organic Sales Up 19.5% >BSX

5 feb 2025, 11:37 UTC

Winsten

Boston Scientific 4Q Adj EPS 70c >BSX

5 feb 2025, 11:37 UTC

Winsten

Boston Scientific Sees FY EPS $1.86-EPS $1.93 >BSX

5 feb 2025, 11:37 UTC

Winsten

Boston Scientific 4Q Sales $4.56B >BSX

5 feb 2025, 11:37 UTC

Winsten

Boston Scientific Sees FY Adj EPS $2.80-Adj EPS $2.87 >BSX

5 feb 2025, 11:37 UTC

Winsten

Boston Scientific Sees 1Q Adj EPS 66c-Adj EPS 68c >BSX

5 feb 2025, 11:37 UTC

Winsten

Boston Scientific Sees 1Q EPS 43c-EPS 45c >BSX

5 feb 2025, 11:37 UTC

Winsten

Boston Scientific 4Q EPS 38c >BSX

Peer Vergelijking

Prijswijziging

Boston Scientific Corp. Prognose

Koersdoel

By TipRanks

18.99% opwaarts potentieel

12 Maanden Prognose

Gemiddelde 120.35 USD  18.99%

Hoogste 135 USD

Laagste 110 USD

Gebaseerd op 23 Wall Street-analisten die 12-maands prijsdoelen bieden voor Boston Scientific Corp. - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Strong Buy

23 ratings

22

Buy

1

Hold

0

Sell

Technische score

By Trading Central

95.25 / 102.37Steun & Weerstand

Korte Termijn

Strong Bullish Evidence

Gemiddeld Termijn

Strong Bearish Evidence

Lange Termijn

No Evidence

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

$

Over Boston Scientific Corp.

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system. It also provides technologies for diagnosing and treating coronary artery disease and aortic valve conditions; WATCHMAN FLX, a Left Atrial Appendage Closure Device; and implantable devices that monitor the heart and deliver electricity to treat cardiac abnormalities, such as cardioverter and cardiac resynchronization therapy defibrillators, MRI S-ICD systems, cardiac resynchronization therapy pacemakers, quadripolar LV leads, ICD leads, pacing leads, remote patient management systems, insertable cardiac monitor systems, and remote cardiac monitoring systems. In addition, the company offers diagnosis and treatment of rate and rhythm disorders of the heart; peripheral arterial and venous diseases; and products to diagnose, treat and ease forms of cancer. The company was incorporated in 1979 and is headquartered in Marlborough, Massachusetts.